Multiple myeloma accounting for 10% of malignancies of haematopoietic system is a heterogenous disease. In the era of individual approach to the patient, we are more and more interested in distinct features and forms of this malignancy. In the article, we described rare MM manifestations with reference to location (central nervous system and skin), M-protein produced by the tumor cells (biclonal and immunoglobulin M), early onset of the disease (young versus old) and pregnancy in MM patients
Ruxolitinib is the first JAK kinase inhibitor registered for the treatment of primary myelofibrosis ...
Mielofibroza (MF) jest heterogennym nowotworem układu krwiotwórczego, cechującym się brakiem chromos...
Zespół del5q stanowi jednostkę chorobową należącą do zespołów mielodysplastcznych. Charakteryzuje si...
Multiple myeloma accounting for 10% of malignancies of haematopoietic system is a heterogenous disea...
Multiple myeloma (MM) is the neoplastic proliferation associated with a variety of neurological mani...
In multiple myeloma extramedullary involvement occurs in 13% of patients. Central nervous system (CN...
Multiple myeloma is a very heterogeneous disease. Though distinctive, several subgroups of the disea...
Multiple myeloma is the neoplastic proliferation of plasma cells. There is a significant heterogenei...
Multiple myeloma (MM) is a malignant and still incurable proliferative disease of the hematopoietic ...
Introduction of new drugs into therapy of multiple myeloma prolonged significantly progression free ...
Central nervous system involvement (CNS) of chronic lymphocytic leukemia (CLL) is a rare complicatio...
Myeloma multiplex (MM) is one of the most common haematological malignancies. In recent years, due t...
The improvement in plasma cell myeloma (PCM) treatment and much longer overall survival of the patie...
Szpiczak plazmocytowy (PCM) stanowi 10% wszystkich nowotworów hematologicznych. U chorych poniżej 65...
Introduction of tyrosine kinase inhibitors (TKI) to therapy of myeloproliferative neoplasms (MPN) im...
Ruxolitinib is the first JAK kinase inhibitor registered for the treatment of primary myelofibrosis ...
Mielofibroza (MF) jest heterogennym nowotworem układu krwiotwórczego, cechującym się brakiem chromos...
Zespół del5q stanowi jednostkę chorobową należącą do zespołów mielodysplastcznych. Charakteryzuje si...
Multiple myeloma accounting for 10% of malignancies of haematopoietic system is a heterogenous disea...
Multiple myeloma (MM) is the neoplastic proliferation associated with a variety of neurological mani...
In multiple myeloma extramedullary involvement occurs in 13% of patients. Central nervous system (CN...
Multiple myeloma is a very heterogeneous disease. Though distinctive, several subgroups of the disea...
Multiple myeloma is the neoplastic proliferation of plasma cells. There is a significant heterogenei...
Multiple myeloma (MM) is a malignant and still incurable proliferative disease of the hematopoietic ...
Introduction of new drugs into therapy of multiple myeloma prolonged significantly progression free ...
Central nervous system involvement (CNS) of chronic lymphocytic leukemia (CLL) is a rare complicatio...
Myeloma multiplex (MM) is one of the most common haematological malignancies. In recent years, due t...
The improvement in plasma cell myeloma (PCM) treatment and much longer overall survival of the patie...
Szpiczak plazmocytowy (PCM) stanowi 10% wszystkich nowotworów hematologicznych. U chorych poniżej 65...
Introduction of tyrosine kinase inhibitors (TKI) to therapy of myeloproliferative neoplasms (MPN) im...
Ruxolitinib is the first JAK kinase inhibitor registered for the treatment of primary myelofibrosis ...
Mielofibroza (MF) jest heterogennym nowotworem układu krwiotwórczego, cechującym się brakiem chromos...
Zespół del5q stanowi jednostkę chorobową należącą do zespołów mielodysplastcznych. Charakteryzuje si...